GLP-1 Market
LLY $1123.00 ▼ -0.1% NVO $44.01 ▼ -1.2% PFE $27.65 ▼ -0.5% VKTX $32.13 ▼ -1.7% KLRA $14.91 ▲ +0.5% GPCR $39.55 ▼ -4.1% RHHBY $53.19 ▼ -0.4% HIMS $27.44 ▼ -1.6% WW $14.78 ▼ -1.1%
Delayed · As of 9:20 AM

Empowering you to have better conversations with your doctor.

Subscribe
About this data Sourced primarily from ClinicalTrials.gov — a listing isn't proof of safety or FDA approval.

Pipeline and clinical trial information here comes primarily from ClinicalTrials.gov. A listing on ClinicalTrials.gov means a study has been registered — not that a treatment is proven safe, effective, or FDA-approved. Investigational treatments may never be approved. Who can join a trial is decided only by that trial's own study team.

Not yet reported

CX11

Company
Vincentage Pharma Co., Ltd
Mechanism
Mechanism not yet reported
Route
Route not yet reported
Recruiting trials
3 recruiting

Efficacy results: Not yet reported

Find a Clinical Trial Near Me

3 recruiting studies currently listed on ClinicalTrials.gov.

Data source: ClinicalTrials.gov · trial data as of Sep 11, 2026

Find a Clinical Trial Near Me

See recruiting studies for CX11 and check eligibility with the study team.

Select conditions
Match
Treatment type

"Added to GLP-1" means the investigational treatment is being studied on top of an existing GLP-1-based therapy.

Your ZIP code is only used to calculate distance to trial sites — it isn't stored.

Trial details
  • Recruiting NCT NCT07340320

    A Study of CX11 Tablets in Patients With Type 2 Diabetes Mellitus

    Not yet reported Corxel Pharmaceuticals 240 participants Est. completion 2027-04-30 48 sites Stand-alone
    Other conditions: Type II Diabetes Mellitus
    View official trial listing →
  • Recruiting NCT NCT07349381

    A Food-Effect Study of CX11 in Healthy Participants

    Not yet reported Vincentage Pharma Co., Ltd 32 participants Est. completion 2026-09-30 1 site Stand-alone
    Type 2 diabetes Other conditions: Obesity & Overweight
    View official trial listing →
  • Recruiting NCT NCT07652047

    A Study to Evaluate the Safety and Tolerability of Different Doses of CX11 Tablets

    Not yet reported Corxel Pharmaceuticals 90 participants Est. completion 2027-06 2 sites Stand-alone
    Other conditions: Obesity & Overweight
    View official trial listing →
  • Completed NCT NCT04221945

    Study of Chemoradiotherapy With or Without Pembrolizumab (MK-3475) For The Treatment of Locally Advanced Cervical Cancer (MK-3475-A18/KEYNOTE-A18/ENGOT-cx11/GOG-3047)

    Not yet reported Merck Sharp & Dohme LLC 1060 participants Est. completion 2026-01-26 176 sites
    Other conditions: Uterine Cervical Neoplasms
    View official trial listing →
  • Active, not recruiting NCT NCT06939296

    A Research Study of VCT220 in Adult Chinese Participants With Obesity

    Not yet reported Vincentage Pharma Co., Ltd 840 participants Est. completion 2026-03-31 1 site
    Other conditions: Obesity, Overweight
    View official trial listing →
  • Completed NCT NCT07011797

    A Study to Evaluate the Efficacy and Safety of CX11 Tablets in Overweight/Obese Participants

    Not yet reported Corxel Pharmaceuticals 250 participants Est. completion 2026-04-09 17 sites Stand-alone
    Other conditions: Obesity
    View official trial listing →
Efficacy history

Not yet reported.

Safety

Not yet reported.

Sources

Also known as: CX11, CX11 (VCT220)

Related On The Pen coverage

No related coverage yet.

This drug may be investigational and not yet approved for any use. Whether someone can join a clinical trial is determined only by that trial's own study team — On The Pen does not determine eligibility. Information here can change; always confirm current details on the official ClinicalTrials.gov listing or with the sponsor.